Paper31375673
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T and 23 others. Nat Commun, 2019. Cited by 54 papers, by iCite.
Cite this record
ConductScience Library. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Papers, record 31375673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31375673
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimetabolites, Antineoplastic | Major topic |
| Biomarkers, Tumor | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| SAM Domain and HD Domain-Containing Protein 1 | Major topic |
| Animals | |
| Azacitidine | |
| Bone Marrow | |
| Cell Line, Tumor | |
| DNA Methylation | |
| Decitabine | |
| Female | |
| Gene Expression Regulation, Leukemic | |
| Humans | |
| Mice | |
| Patient Selection | |
| Primary Cell Culture | |
| Retrospective Studies | |
| Treatment Outcome | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21 AI136737 | NIAID NIH HHS | United States | R21AI136737 | PubMed | NIH RePORTER |
| T32 GM008283 | NIGMS NIH HHS | United States | T32GM008283 | PubMed | NIH RePORTER |
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28693797 | Azacitidine in adult patients with acute myeloid leukemia. | Crit Rev Oncol Hematol | 2017 | https://conductscience.org/library/papers/28693797 | PubMed |
| 2 | 25644037 | Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. | Sci Rep | 2015 | https://conductscience.org/library/papers/25644037 | PubMed |
| 3 | 25755265 | A High-Throughput Enzyme-Coupled Assay for SAMHD1 dNTPase. | J Biomol Screen | 2015 | https://conductscience.org/library/papers/25755265 | PubMed |
| 4 | 29339097 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29339097 | PubMed |
| 5 | 27330573 | A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. | Clin Epigenetics | 2016 | https://conductscience.org/library/papers/27330573 | PubMed |
| 6 | 25716206 | Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. | Blood | 2015 | https://conductscience.org/library/papers/25716206 | PubMed |
| 7 | 30084010 | Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes. | Ann Hematol | 2018 | https://conductscience.org/library/papers/30084010 | PubMed |
| 8 | 29543073 | Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. | Expert Rev Hematol | 2018 | https://conductscience.org/library/papers/29543073 | PubMed |
| 9 | 19230772 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19230772 | PubMed |
| 10 | 1710634 | A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. | J Immunol Methods | 1991 | https://conductscience.org/library/papers/1710634 | PubMed |
| 11 | 20702620 | Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. | J Virol | 2010 | https://conductscience.org/library/papers/20702620 | PubMed |
| 12 | 11483751 | Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. | J Virol | 2001 | https://conductscience.org/library/papers/11483751 | PubMed |
| 13 | 25015816 | Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. | J Immunol | 2014 | https://conductscience.org/library/papers/25015816 | PubMed |
| 14 | 29708172 | Current PD-L1 immunohistochemistry for non-small cell lung cancer. | J Thorac Dis | 2018 | https://conductscience.org/library/papers/29708172 | PubMed |
| 15 | 25267621 | Structural basis of cellular dNTP regulation by SAMHD1. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/25267621 | PubMed |
| 16 | 22439938 | Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22439938 | PubMed |
| 17 | 25532805 | Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. | Cell Host Microbe | 2015 | https://conductscience.org/library/papers/25532805 | PubMed |
| 18 | 15572771 | REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. | Acta Crystallogr D Biol Crystallogr | 2004 | https://conductscience.org/library/papers/15572771 | PubMed |
| 19 | 28209616 | OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. | Cancer Res | 2017 | https://conductscience.org/library/papers/28209616 | PubMed |
| 20 | 29670289 | SAMHD1 acts at stalled replication forks to prevent interferon induction. | Nature | 2018 | https://conductscience.org/library/papers/29670289 | PubMed |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42925407 | Decitabine and azacitidine exert multifaceted effects beyond DNA hypomethylation in myeloid neoplasms. | Int J Hematol | 2026 | https://conductscience.org/library/papers/42925407 | PubMed |
| 42592050 | Nucleotide Metabolism in Health and Disease. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42592050 | PubMed |
| 42340493 | Predicting response to hypomethylating agents in myeloid neoplasms: a robust model. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42340493 | PubMed |
| 41888396 | Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/41888396 | PubMed |
| 41748545 | RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41748545 | PubMed |
| 41617034 | Allosteric targeting with antiviral nucleotide analogs allows fine-tuning of SAMHD1 dNTPase activity. | J Biol Chem | 2026 | https://conductscience.org/library/papers/41617034 | PubMed |
| 41577852 | Efficacy of azacitidine in meningiomas and explorative analyses of underlying molecular mechanisms. | Neurosurg Rev | 2026 | https://conductscience.org/library/papers/41577852 | PubMed |
| 41503213 | Prognostic value of BTG1 for predicting decitabine sensitivity in de novo acute myeloid leukemia. | iScience | 2026 | https://conductscience.org/library/papers/41503213 | PubMed |
| 41392286 | Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/41392286 | PubMed |
| 41370931 | Targeting Genome Maintenance Defects of Cancers Using Chain-Terminating Nucleoside Analogs. | Cancer Sci | 2026 | https://conductscience.org/library/papers/41370931 | PubMed |
| 41057684 | Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial. | Leukemia | 2025 | https://conductscience.org/library/papers/41057684 | PubMed |
| 40902696 | Continuous assay for the dNTP triphosphohydrolase of activated SAMHD1. | Anal Biochem | 2026 | https://conductscience.org/library/papers/40902696 | PubMed |
| 40533858 | Advances and challenges in the treatment of myelodysplastic syndromes. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/40533858 | PubMed |
| 40507894 | Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40507894 | PubMed |
| 40362245 | From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362245 | PubMed |
| 39003408 | Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia. | Clin Exp Med | 2024 | https://conductscience.org/library/papers/39003408 | PubMed |
| 38906675 | The type of DNA damage response after decitabine treatment depends on the level of DNMT activity. | Life Sci Alliance | 2024 | https://conductscience.org/library/papers/38906675 | PubMed |
| 38760575 | Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS. | EMBO J | 2024 | https://conductscience.org/library/papers/38760575 | PubMed |
| 38710701 | Platform-directed allostery and quaternary structure dynamics of SAMHD1 catalysis. | Nat Commun | 2024 | https://conductscience.org/library/papers/38710701 | PubMed |
| 38406263 | SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients. | NAR Cancer | 2024 | https://conductscience.org/library/papers/38406263 | PubMed |
Genes37
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31375673
GET https://conductscience.org/api/papers/v1/31375673/authors?page=2